ZIOPHARM Oncology Inc (NASDAQ:ZIOP)

11.92
Delayed Data
As of Apr 17
 -0.035 / -0.29%
Today’s Change
2.31
Today|||52-Week Range
14.40
+135.01%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. The company also has a portfolio of small molecule drug candidates, which are no longer a strategic focus of its development activities for which the company is seeking partners to pursue further development and commercialization. It is currently focused on two clinical stage product candidates: Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex. Ziopharm Oncology was founded on September 9, 2003 and is headquartered in Boston, MA.

Contact Information

ZIOPHARM Oncology, Inc.
Parris Building
Boston Massachusetts 02129
P:(617) 259-1970
Investor Relations:

Employees

Shareholders

Individual stakeholders28.88%
Other institutional21.81%
Mutual fund holders10.76%

Top Executives

Jonathan J. LewisChief Executive Officer & Director
Kevin G. LafondChief Financial Officer, Treasurer, CAO & VP
J. Kris PiperVice President-Clinical Regulatory & Quality
Francois LebelSVP-Clinical Development & Medical Operations
Caesar J. BelbelSecretary, Chief Legal Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account